Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

Inclusion Criteria: * Alpha-feto protein \> 400 ng / mL or * prior ultrasound with mass suspicious for hepatic malignancy or. * clinical risk of hepatocellular carcinoma or * prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma Exclusion Criteria: * Glomerulo-filtration rate \< 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study * Previous diagnosis of hepatic malignancy * Any conditions that would discount the ability to have an MRI scan